Targeting long non-coding RNA MALAT1 alleviates retinal neurodegeneration in diabetic mice

Yu-Lan Zhang, Han-Ying Hu, Zhi-Peng You, Bing-Yang Li, Ke Shi

Department of Ophthalmology, the Second Affiliated Hospital, Nanchang University, Nanchang 330006, Jiangxi Province, China

Co-first authors: Yu-Lan Zhang and Han-Ying Hu
Correspondence to: Ke Shi. Department of Ophthalmology, the Second Affiliated Hospital of Nanchang University, No.1 Minde Rd, Nanchang 330006, Jiangxi Province, China. 86325294@qq.com

Received: 2019-07-12 Accepted: 2019-11-05

Abstract
- **AIM:** To observe the effect of inhibiting long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) on diabetic neurodegeneration.
- **METHODS:** Thirty-six 8-week-old C57BL/6 mice were randomly divided into normal control, diabetic control, diabetic scrambled small interfering RNAs (siRNAs) and diabetic MALAT1-siRNA groups. After diabetic induction with streptozocin intraperitoneally-injection, the diabetic MALAT1-siRNA group was intravitreally injected with 1 μL 20 μmol/L MALAT1 siRNA, and the diabetic scrambled siRNA group was injected with the same amount of scrambled siRNA. Electroretinography was performed to examine photoreceptor functions 16wk after diabetes induction. MALAT1 expression was detected via real time polymerase chain reaction. Cone morphological changes were examined using immunofluorescence. Rod morphological changes were examined by determining outer nuclear layer (ONL) thickness.
- **RESULTS:** The upregulation of retinal MALAT1 expression was detected in the diabetic control mice, while MALAT1 expression in the diabetic MALAT1-siRNA mice was decreased by 91.48% compared to diabetic control mice. The diabetic MALAT1-siRNA and diabetic control mice showed lower a-wave and b-wave amplitudes than did the normal control mice in scotopic and photopic electroretinogram, while the diabetic MALAT1-siRNA mice showed higher amplitudes than diabetic control mice. Morphological examination revealed that ONL thickness in the diabetic MALAT1-siRNA and diabetic control mice was lower than normal control mice. However, ONL thickness was greater in the diabetic MALAT1-siRNA mice than diabetic control mice. Moreover, the diabetic control mice performed a sparser cone cell arrangement and shorter outer segment morphology than diabetic MALAT1-siRNA mice.
- **CONCLUSION:** Inhibiting retinal MALAT1 results in mitigative effects on the retinal photoreceptors, thus alleviating diabetic neurodegeneration.
- **KEYWORDS:** long non-coding RNA MALAT1; small interfering RNA; diabetic retinopathy; neurodegeneration

INTRODUCTION

The International Diabetes Federation predicts that the number of diabetes mellitus (DM) patients will add up to 642 million in 2040[1]. Diabetic retinopathy (DR) is a serious complication of diabetes and the leading cause of blindness in the global working population. DR has been recognized as a microvascular and neurodegenerative disorder. Excessive oxidative stress, activation of protein kinase C, and production of glycation ends products under a high glucose environment in the retina damage retinal cells and tissues, including photoreceptors and other neurons[2-3]. Photoreceptor degeneration is the main cause of color vision abnormalities and contrast sensitivity abnormalities in patients with diabetes before DR; moreover, this degeneration is an important early pathological change in DR[4]. Verma et al[5] employed spectral-domain optical coherence tomography (SD-OCT) to measure the thickness of the retinal photoreceptor layer in patients with diabetes but no signs of DR. In this study, the photoreceptor layer was thinner in patients than in controls. Therefore, exploring protection against retinal neurodegeneration under diabetic conditions to preserve the visual function of patients as much as possible is of great significance.

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved, folded, non-coding RNA that is primarily expressed in the nucleus. MALAT1 was originally identified in tumor tissue specimens with upregulated
expression. MALAT1 is involved in the regulation of tumor cell proliferation, invasion, metabolism and migration\(^6\). In addition, according to Michalik \textit{et al}\(^9\), MALAT1 regulates the biological functions of vascular endothelial cells. Silencing of MALAT1 expression inhibits cell proliferation and reduces retinal neovascularization. However, the role of MALAT1 in neurodegenerative diseases remains unclear. In the present study, small interfering RNAs (siRNAs) was used to downregulate retinal MALAT1 to examine and compare electroretinogram (ERG) amplitude, outer nuclear layer (ONL) thickness, cone density and morphological changes in diabetic mice model to determine changes in photoreceptor cell function and morphology as well as to investigate the effect of inhibiting retinal long non-coding (IncRNA) MALAT1 on diabetic retinal neurodegeneration.

\textbf{MATERIALS AND METHODS}

\textbf{Ethical Approval} This study was conformed to the Animal Research: Reporting of \textit{In Vivo} Experiments (ARRIVE) guidelines and was accorded with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All mice were anesthetized and sacrificed using acceptable methods by a skilled technician. The protocol was approved by the Nanchang University Committee on the Ethics of Animal Experiments.

\textbf{Reagents and Instruments} The following materials were utilized in the present study: streptozotocin (STZ) and RNA extraction kit (Sigma-Aldrich, Germany), protein content determination kit (Bio-Rad, Hercules, CA, USA), rabbit anti-mouse S-opsin primary antibody (Millipore, Billerica, MA, USA), goat anti-rabbit fluorescent secondary antibody (Vector Inc., Burlingame, CA, USA), citrate buffer (Beijing Tiangen Biotech), electronic analytical balance (Shanghai Jingke Balance Factory), compound tropicamide eye drops (Santen Pharmaceutical, Osaka, Japan), recombinant bovine basic fibroblast growth factor ophthalmic gel (Zhuhai Essex Pharmaceutical), electroretinography system (Diagnosys, Westford, MA, USA), StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and inverted fluorescence microscope (Olympus Corporation, Tokyo, Japan).

\textbf{Experimental Animals and Groups} Thirty-six healthy eight weeks old male C57BL/6 mice with no ocular diseases (weighing 20-30 g and clean grade) were purchased from the Department of Animal Science of Nanchang University [license No.SYXX(JX)2015-0001]. All mice were kept at temperature of 18°C-23°C, humidity of 40%-60% with a cycle of 14h light and 10h dark. Except fasting for diabetes establishment, food and water available at all times. The mice were randomly divided into four groups: normal control group, diabetic control group, diabetic scrambled siRNA group and diabetic MALAT1 siRNA group. A diabetes model induced by STZ was employed in the latter three groups using a previously established method\(^9\). Briefly, mice were intraperitoneally injected with STZ for 5 consecutive days after an 8h fast. STZ was freshly dissolved in 0.01 mol/L citrate buffer with pH 4.5 before injection. Mice in these three groups were intraperitoneally injected with 50 mg/kg STZ, while mice in the normal control group were given the same volume of citrate buffer. On the 7th day after first injection, blood samples were collected from the tail vein of normally fed mice to measure blood glucose concentration. Effective induction of the diabetes was defined as glucose levels greater than 300 mg/dL. Same blood glucose measurement was operated at week 16 after first STZ injection.

\textbf{Synthesis of MALAT1 siRNA} Effective siRNA sequences were designed on the report of PubMed and submitted to Shanghai GenePharma corporation to synthesize MALAT1-targeting siRNA using the following sequences: 5’-GAUUGAAGCUAGCAAUAAG-3’ as the sense strand and 5’-UUGAUUGCAUGCCUUACAUUCU-3’ as the antisense strand. Nontargeting siRNA was synthesized as a negative control. siRNA was dissolved in diethyl pyrocarbonate (DEPC)-treated normal saline to prepare a 20 μmol/L solution.

\textbf{Intravitreal Injection of siRNA} Compound of ketamine (100 mg/kg) and xylazine (10 mg/kg) was injected intraperitoneally to anesthetize mice. The periocular region was disinfected with iodophor after subjecting mice to intraperitoneal anesthesia. The needle of a Hamilton micro syringe was inserted toward the posterior pole from 1 mm outside the limbus under microscope, and the test article was slowly injected once the needle tip was visible in the pupil. Both eyes of the diabetic MALAT1 siRNA group was intravitreally injected with a mixture of 1 μL 20 μmol/L MALAT1 siRNA and 1 μL transfection reagent, while both eyes of the diabetic scrambled siRNA group were intravitreally injected with a mixture of 1 μL 20 μmol/L scrambled siRNA and 1 μL transfection reagent. The repeated injection were carried out in the following 2, 4, 6, 8wk.

\textbf{Electroretinogram} ERG was performed 16wk after first STZ injection. Mice were treated with compound tropicamide eye drops for pupil dilation and were placed in a dark room overnight, followed by anesthesia as mentioned above. Then, mice were placed on a heated plate. A reference electrode and ground electrode were inserted into the palate and tail, respectively. Platinum corneal electrodes was placed on the cornea of both eyes and lubricated with recombinant bovine basic fibroblast growth factor ophthalmic gel. The above procedures were completed under a dim red-light lamp in a dark room. Scotopic ERG responses were recorded under luminous intensities of 0.0004, 0.04, 4, 400 and 2000 cd/s/m². Next, the light was turned on, and mice adapted for 10min.
Photopic ERG responses were recorded under luminous intensities of 2000 cd·s/m².

**Real-time Polymerase Chain Reaction** Real-time polymerase chain reaction (PCR) was conducted 16wk after first STZ injection. Retinal tissues were collected from euthanized mice. RNA Purification Kit was used to extract total RNA. Reverse transcription was operated using a Takara reverse transcription kit to acquire total DNA. MALAT1 and TNF-α target genes and the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) internal reference gene were amplified. The amplification conditions were as follows: predenaturation at 94°C for 60s, 36 cycles of denaturation at 94°C for 10s, and annealing/extension at 56°C for MALAT1 and 61°C for TNF-α and GAPDH for 30s. The gene copy number was calculated. The ratio of the copy number of MALAT1 and TNF-α to the copy number of the GAPDH was used as the relative expression level of MALAT1 and TNF-α. The primers used in real-time PCR were as follows: mouse MALAT1 sense 5'-CATGGCCGAATTGCTGTTA-3', antisense 5'-CTGGCAGACAGCATACGA-3'; mouse TNF-α sense 5'-GCCTCTTCTCAATTCCTTG-3', antisense 5'-CTGATGAGGGAGGCCATT-3'; mouse GAPDH sense 5'-TGCCCCCATGTGTTGATG-3', antisense 5'-TGTGTCATGACCTTCCC-3'.

**Measurement of Retinal Outer Nuclear Layer Thickness** Sixteen weeks after the establishment of diabetes model, eyeballs were removed from euthanized mice and directly fixed in 4% paraformaldehyde for 1h at room temperature. After washing in phosphate buffer saline (PBS) 4% paraformaldehyde for an additional 15min at room temperature. No statistically significant differences in body mass were found among the four groups following initial model establishment (P>0.05). However, body mass was greater in the normal group than in the diabetic control, diabetic scrambled siRNA and MALAT1 siRNA groups. Seven days after first intraperitoneal injection of STZ, mice had blood glucose levels higher than 300 mg/dL. The success rate of diabetes modeling was 100%. Body mass and blood glucose levels were measured at day 7 and week 16 after first STZ injection. No statistically significant differences in body mass were found among the four groups following initial model establishment (P>0.05). However, body mass was greater in the normal group than in the diabetic control, diabetic scrambled siRNA and MALAT1 siRNA groups by 41.99%, 45.23%, and 34.73%, respectively, at week 16 after model establishment (P<0.05). The three diabetic mouse groups were thinner and had higher water and food intake as well as urine output than did the normal control group. At 7d and week 16 after first STZ injection, the blood glucose concentration in the normal control mice were 46.26% and 49.72% lower than those in the diabetic control mice, 46.79% and 52.08% lower than those in the diabetic scrambled siRNA group, and 47.26% and 50.89% lower than those in the diabetic MALAT1 siRNA group, respectively. These differences were significant (P<0.05). However, no differences were detected in blood glucose concentration among the diabetic control mice, diabetic scrambled siRNA mice and diabetic MALAT1 siRNA mice at 0 and 16wk (Table 1).

**Retinal Expression of MALAT1 and Downstream Target TNF-α** RT-PCR was employed to detect the expression of MALAT1 and its downstream target TNF-α in mouse retinas. According to analyses, MALAT1 was upregulated under diabetic conditions. However, retinal MALAT1 expression was downregulated in mice after treatment with MALAT1 siRNA. Retinal MALAT1 expression was approximately
216

43.98% lower than that of the normal control group, and it was only 8.52% and 8.90% of the level of the diabetic control and diabetic scrambled siRNA groups, respectively. The differences were significant (P<0.05; Figure 1A). The expression of the downstream target TNF-α was also decreased in the diabetic MALAT1 siRNA group. Retinal TNF-α expression was approximately 26.89% and 28.03% of the level of the diabetic control and diabetic scrambled siRNA groups, respectively. The differences were significant (P<0.05; Figure 1B).

Morphological and Functional Changes in Rod Cells

Scotopic ERG stimulates mouse retinas with gradient luminous intensity in a dark environment and reflects the function of rod cells[8]. The ERGs of the four groups are shown in Figure 2A-2C. The diabetic control, diabetic scrambled siRNA and diabetic MALAT1 siRNA groups showed significantly lower a-wave and b-wave amplitudes in scotopic ERG than did the normal control group (P<0.05). However, the MALAT1 siRNA group exhibited significantly higher a-wave and b-wave amplitudes in scotopic ERG than did the diabetic control and diabetic scrambled siRNA groups (P<0.05; Figure 2D-2H).

The retinal ONL mainly comprises photoreceptor nuclei. Because 98% of photoreceptor cells are rod cells, the thickness of the ONL basically reflects changes in the number of rod cells[4,11]. In the present study, retinal ONL thickness was measured at 0.48, 0.96, 1.44, and 1.92 mm above and below the optic nerve head. The ONL thickness of the diabetic MALAT1 siRNA, diabetic scrambled siRNA and diabetic control groups was decreased by 16.05%, 36.67% and 35.38%, respectively, compared to that of the normal control group. However, the ONL of the diabetic MALAT1 siRNA group was 28.91% and 27.65% thicker than that of the diabetic control and diabetic scrambled siRNA groups, respectively. These differences were significant (P<0.05; Figure 2D-2H).

Morphological and Functional Changes in Cone Cells

Photopic ERG was used to measure the function of cone photoreceptor[9]. Photopic ERG a-wave and b-wave amplitudes in the diabetic control, diabetic scrambled siRNA and diabetic MALAT1 siRNA mice were significantly lesser than those in the normal control mice (P<0.05). By contrast, photopic ERG a-wave and b-wave amplitudes in the diabetic MALAT1 siRNA group were greater than those in the diabetic control and diabetic scrambled siRNA mice (Figure 3A-3C). Morphological changes using s-opsin for labelling were examined with immunofluorescence[9,12]. Compared with the normal control mice, the diabetic control, diabetic scrambled siRNA and diabetic MALAT1 siRNA mice manifested lower cone photoreceptor density with a sparse arrangement. However, changes in the diabetic control and diabetic scrambled siRNA treated mice were more obvious with dwarfish outer segments than those in the diabetic MALAT1 siRNA treated mice (Figure 3D-3G).

DISCUSSION

DR is the most frequent ocular complication of diabetes and one of the major blinding diseases in people over 50 years old. DR was initially considered a diabetic microangiopathy. Retinal neuronal cell death is accumulated in animal models of...
Figure 2 Scotopic ERG and ONL thickness changes in diabetic mice

A: Representative graph of scotopic ERG; B: Statistical analysis of a-wave amplitudes in scotopic ERG (n=6, mean±SEM); C: Statistical analysis of b-wave amplitudes in scotopic ERG (n=6, mean±SEM); D: Retinal ONL of normal control mice; E: Diabetic control mice; F: Diabetic scrambled siRNA treated mice; G: Diabetic MALAT1 siRNA treated mice; H: Statistical analysis of ONL thickness (n=6, mean±SD). Scale bar: 40 μm. *P<0.05 vs normal control group, †P<0.05 vs diabetic control group.

diabetes, and abnormal glial fibrillary acidic protein (GFAP) expression in astrocytes and Müller cells as well as microglial activation occurs in diabetic animal models. Based on these findings, DR is also considered a chronic neurodegenerative disease. Photoreceptor cells, including cones and rods, are important retinal neurons involved in the primary visual pathway. As mentioned earlier, photoreceptor degeneration is an important early pathological change in DR. According to current research, the possible mechanisms of neurodegeneration in DR include oxidative stress\(^{[13]}\), increased glycation end products\(^{[14]}\), and activation of the renin angiotensin system\(^{[15]}\).

lncRNA is widely present in organisms. As a transcript greater than 200 bp, non-coding RNA can regulate gene expression at the epigenetic, transcriptional and posttranscriptional levels, thereby affecting cell proliferation, cell apoptosis, cell activity, immune response and oxidative stress. MALAT1 is a 7 kb, highly conserved, folded non-coding RNA that is primarily expressed in the nucleus. In recent years, MALAT1 has been involved in the pathogenesis of diabetic ocular lesions. According to Yan et al\(^{[16]}\), the expression of MALAT1 is upregulated in RF/6A cells under high glucose conditions as well as in the aqueous humor and proliferative fibrous membrane specimens of patients with DR. Downregulation of MALAT1 attenuates the deterioration of retinal function and alleviates retinal vascular damages caused by diabetes. Moreover, downregulation of MALAT1 reduces the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), thereby improving the ocular microvascular dysfunction caused by diabetes\(^{[17]}\). In addition, MALAT1 plays a role in neurologically related lesions. Based on a study by Bernard et al\(^{[19]}\), MALAT1 regulates gene expression related to nuclear and synaptic functions as well as synaptogenesis in neurons. Kryger et al\(^{[19]}\) found that MALAT1 is upregulated in the cerebellum, hippocampus and brainstem of alcoholics. However, reports on MALAT1 in diabetic retinal neurodegeneration are scarce. According to Yao et al\(^{[20]}\), MALAT1 expression is increased in the retina of rats and mice following optic nerve transection, and MALAT1 knockdown inhibits Müller cell activation. MALAT1 dysregulation may also affect retinal ganglion cell survival and alter the development of glaucomatous neurodegeneration.

siRNAs are RNA fragments composed of 19-21 bp that can degrade the RNA of specific genes, thereby inhibiting the expression of these genes. In the present study, MALAT1 expression was downregulated in the retina of mice treated with MALAT1 siRNA. The effect of downregulation of MALAT1 on the function and morphology of photoreceptors was evaluated with various indicators. Flash ERG uses flashes of different light intensities to stimulate photoreceptor cell hyperpolarization, that can be detected noninvasively through a platinum electrode placed on the cornea\(^{[4]}\). Scotopic and photopic ERGs are frequently used to reflect the functional status of rods and cones, respectively. According to previous studies, diabetic rats have abnormal ERGs at an early stage\(^{[21]}\). A gradually decreasing ERG amplitude has been observed with disease progression in patients with DR as indicated
In the present study, a-wave and b-wave amplitudes in scotopic and photopic ERG in the diabetic MALAT1 siRNA treated mice were lesser than those in the normal control mice but greater than those in the diabetic control and diabetic scrambled siRNA treated mice. These results suggested that downregulation of MALAT1 by siRNA alleviated functional impairments in photoreceptor cells in diabetic mice.

Retinal photoreceptor cells are divided into rod cells and cone cells according to the morphology of their outer segments. Rod cells account for more than 90% of photoreceptor cells. Therefore, the ONL of the retina mainly comprises the nuclei of rod cells, and its thickness reflects cell death and morphological changes in rod cells. Animal studies have confirmed that the thickness of ONL in diabetic rats is progressively reduced with the progression of the disease course. The present study also found that the ONL thickness of the three diabetic mouse groups was less than that of the normal control group 16wk after model establishment, suggesting that the retinal rod cells of the diabetic mouse model in this study were continuously dying. However, the ONL thickness of the MALAT1 siRNA treated mice was greater than that of the diabetic control and diabetic scrambled siRNA treated mice at each time point. Since s-opsin responds to high intensity light and color in cones and is mainly distributed on the outer segment, we used s-opsin to label the cone outer segments for immunofluorescence to observe changes in cone cell structure. As mentioned above, the diabetic control and diabetic scrambled siRNA groups had a sparser cone arrangement and shorter outer segment morphology than did...
the diabetic MALAT1 siRNA group. These results suggested less damage to rods and cones in the MALAT1 siRNA-treated group despite the persistent death of photoreceptor cells under diabetic conditions, indicating that downregulation of MALAT1 has a protective effect on photoreceptor cells.

In summary, compared with regular diabetic mice, diabetic mice that received local injections of MALAT1 siRNA to inhibit MALAT1 expression in the retina showed reduced functional and morphological lesions of retinal photoreceptor cells. These results suggested that MALAT1 interference may become a novel orientation for the clinical application of intervention and therapy on diabetic neurodegeneration.

ACKNOWLEDGEMENTS

Foundations: Supported by National Natural Science Foundation of China (No.81960158, No.81760176); Key Scientific research Program of Jiangxi Education Department Foundation of China (No.81960158, No.81760176); Key

REFERENCES